PET Tracer F-18-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models

Shuntaro Oka, Nihon Mediphys Co. Ltd
Masaru Kanagawa, Nihon Mediphys Co. Ltd
Yoshihiro Doi, Nihon Mediphys Co. Ltd
David Schuster, Emory University
Mark Goodman, Emory University
Hirokatsu Yoshimura, Nihon Mediphys Co. Ltd

Journal Title: Theranostics
Volume: Volume 7, Number 7
Publisher: Ivyspring International Publisher | 2017-01-01, Pages 2048-2064
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.7150/thno.19883
Permanent URL: https://pid.emory.edu/ark:/25593/s3c3j

Final published version: http://dx.doi.org/10.7150/thno.19883

Copyright information:
© Ivyspring International Publisher.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).

Accessed October 16, 2024 3:20 PM EDT
PET Tracer \(^{18}\text{F}\)-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models

Shuntaro Oka\(^1\), Masaru Kanagawa\(^1\), Yoshihiro Doi\(^1\), David M. Schuster\(^2\), Mark M. Goodman\(^2\), Hirokatsu Yoshimura\(^1\)

1. Research Center, Nihon Medi-Physics Co., Ltd., Chiba, Japan;
2. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.

Received: 2017.03.01; Accepted: 2017.04.08; Published: 2017.05.15

Abstract

\(^{18}\text{F}\)-Fluciclovine (trans-1-amino-3-\(^{18}\text{F}\)-fluorocyclobutane-carboxylic acid; \(\text{anti-}^{18}\text{F-FACBC}\)) is a positron emission tomography (PET) tracer for diagnosing cancers (e.g., prostate and breast cancer). The most frequent metastatic organ of these cancers is bone. Fluciclovine-PET can visualize bony lesions in clinical practice; however, such lesions have not been described histologically.

Methods: We investigated the potential of \(^{14}\text{C}\)-fluciclovine in aiding the visualization of osteolytic and osteoblastic bone metastases (with histological analyses), compared with \(^{3}\text{H}\)-2-deoxy-2-fluoro-D-glucose (\(^{3}\text{H}\)-FDG), \(^{1}\text{H}\)-choline chloride (\(^{1}\text{H}\)-choline), and \(^{99m}\text{Tc}\)-hydroxyethylene diphosphonate (\(^{99m}\text{Tc}\)-HMDP) by using triple-tracer autoradiography in rat breast cancer osteolytic (on day 12 \(\pm\) 1 postinjection of MRMT-I) and prostate cancer osteoblastic (on day 20 \(\pm\) 3 postinjection of AT6.1) metastatic models.

Results: The distribution patterns of \(^{14}\text{C}\)-fluciclovine, \(^{3}\text{H}\)-FDG, and \(^{1}\text{H}\)-choline, but not \(^{99m}\text{Tc}\)-HMDP, were similar in both models, and the lesions where these tracers accumulated were, histologically, typical osteolytic and osteoblastic lesions. \(^{99m}\text{Tc}\)-HMDP accumulated mostly in osteoblastic lesions. \(^{14}\text{C}\)-fluciclovine could visualize the osteolytic lesions as early as day 6 postinjection of MRMT-I. However, differential distributions in \(^{14}\text{C}\)-fluciclovine and \(^{3}\text{H}\)-FDG existed, based on histological differences: low \(^{14}\text{C}\)-fluciclovine and high \(^{3}\text{H}\)-FDG accumulation in osteolytic lesions with inflammation. In the osteoblastic metastatic model, visualization of osteoblastic lesions with \(^{14}\text{C}\)-fluciclovine was not clear, yet clearer than with \(^{3}\text{H}\)-FDG. Although half of the osteoblastic lesions with \(^{14}\text{C}\)-fluciclovine accumulation showed negligible \(^{3}\text{H}\)-choline accumulation in comparison, they were histologically similar to lesions with marked \(^{14}\text{C}\)-fluciclovine and \(^{3}\text{H}\)-choline accumulation.

Conclusion: These results suggest that fluciclovine-PET can visualize true osteolytic and osteoblastic bone metastatic lesions.

Key words: breast cancer, fluciclovine, osteolytic/osteoblastic metastasis, prostate cancer, triple-tracer autoradiography.
Introduction

Breast cancer (BCa) and prostate cancer (PCa) are the most common primary tumors for women and men, respectively, and for patients with bone metastasis [1]. The 5-year survival rates of BCa and PCa are approximately 99% if the cancers are localized [2]. Approximately 4%-5% of patients with BCa and PCa have distant metastasis, including metastasis to the bone; however, their 5-year survival rates decrease to 25% and 28%, respectively [2]. Thus, accurate early diagnosis of bone metastasis is important in planning therapeutic strategies for PCa and BCa.

Bone metastases of PCa and BCa are predominantly osteoblastic and mixed osteolytic/osteoblastic metastasis, respectively, although most patients have both of these lesions [3]. A bone scan using \(^{99m}\)Tc-hydroxymethylene diphosphonate (\(^{99m}\)Tc-HMDP)/\(^{99m}\)Tc-methylene diphosphonate (\(^{99m}\)Tc-MDP) is most commonly used to diagnose bone metastases. A bone scan is sufficiently sensitive to detect advanced skeletal metastatic lesions, but not early-stage bone metastases [4]. In addition, the specificity of a bone scan is limited because many other pathological conditions involve osteoblastic reactions—the identification of which is the basis of this technique [4]. Compared to bone scan, positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-\(^{18}\)F-fluoro-D-glucose (\(^{18}\)F-FDG) has the advantage of detecting metastatic sites, including osteolytic lesions; however, it is not helpful in the diagnosis of osteoblastic lesions because these lesions have fewer malignant cells than osteolytic lesions [5]. Another PET tracer, \(^{11}\)C/\(^{18}\)F-choline chloride (\(^{11}\)C/\(^{18}\)F-choline) shows high sensitivity and specificity for detecting bone metastasis of PCa [6]; however, the relatively high uptake of \(^{11}\)C/\(^{18}\)F-choline or \(^{18}\)F-FDG by macrophages may cause false-positive imaging results [7]. There are many reviews on the potential of \(^{18}\)F-FDG-PET, \(^{11}\)C/\(^{18}\)F-choline, and bone scan for the detection of bone metastases in patients with PCa and/or BCa [8–13].

\(^{18}\)F-Flucilovine, also called trans-1-amino-3-\(^{18}\)F-fluorocyclobutanecarboxylic acid (anti-\(^{18}\)F-FACBC; code name, NMK36, Nihon Medi-Physics; brand name, Axumin, Blue Earth Diagnostics), is an amino acid PET tracer that is transported by alanine-serine-cysteine transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) [14–16]. The main characteristic of our PET tracer is its low uptake by inflammatory cells (e.g., macrophages) compared to \(^{18}\)F-FDG [15]. \(^{18}\)F-Flucilovine-PET has been used for diagnosing cancers such as PCa [17–19], BCa [20,21], and glioma [22,23], in primary cancer and in nodal and bone involvement. In combination with external-beam radiotherapy, image-guided radiotherapy based on \(^{18}\)F-Flucilovine-PET has become possible in post-prostatectomy patients with recurrent PCa [24–26]. In cancer patients with bone metastasis, radiotherapy plays an important role not only with regard to its tumoricidal effect, but also in bone pain relief [27]. Therefore, if image-guided radiotherapy with \(^{18}\)F-Flucilovine-PET is to be applied for bone therapy, accurate diagnostic information such as the number and the location of bone metastatic lesions is required. Although \(^{18}\)F-Flucilovine-PET can reveal the number and the location of bony lesions [19], a few reports have demonstrated histological proof of \(^{18}\)F-Flucilovine accumulation in bone metastatic lesions. Moreover, these studies were limited to osteolytic metastasis [17,18]. Thus, we believe it is worthwhile to explore the ability of \(^{18}\)F-Flucilovine to detect osteolytic and osteoblastic bone metastatic lesions, with histological validation.

In this study, we investigated the potential of \(^{18}\)F-Flucilovine to aid the visualization of osteolytic and osteoblastic bone metastases with pathological analyses, compared to visualization using \(^{18}\)F-FDG, \(^{11}\)C/\(^{18}\)F-choline, and \(^{99m}\)Tc-HMDP by using triple-tracer autoradiography in rat BCa osteolytic and PCa osteoblastic metastatic models.

Materials and Methods

Chemicals

All reagents were purchased from Life Technologies (Carlsbad, CA, USA), Sigma-Aldrich (St. Louis, MO, USA), Nacalai Tesque (Kyoto, Japan), and Wako Pure Chemical Industries (Osaka, Japan), unless otherwise stated. \(^{1}\)C-labeled flucilovine and \(^{3}\)H-labeled FDG or choline were used instead of \(^{11}\)C/\(^{18}\)F-labeled tracers because their long half-lives make them more suitable for experiments than tracers labeled with \(^{11}\)C (20 minutes) or \(^{18}\)F (110 minutes). \(^{11}\)C-Flucilovine (trans-1-amino-3-fluoro[1-\(^{14}\)C]cyclobutanecarboxylic acid; specific activity [SA], 2.08 GBq/mmol; radiochemical purity (RCP), >98%) was commercially synthesized by Nemoto Science (Tokyo, Japan), as described previously [14]. [5,6-\(^{3}\)H]-2-Fluoro-2-deoxy-D-glucose (\(^{3}\)H-FDG; catalog number: ART0105; SA, 2.22 TBq/mmol; RCP, >99%) was purchased from American Radiolabeled Chemicals (St. Louis, MO, USA). [methyl-\(^{3}\)H]-Choline chloride (\(^{3}\)H-choline; catalog number: NET109; SA, 2.897 TBq/mmol; RCP, >97%) was obtained from PerkinElmer (Waltham, MA, USA). Our company, Nihon Medi-Physics (Tokyo, Japan), produced \(^{99m}\)Tc-HMDP (740 MBq/vial; RCP, >95%).
**Cell culture**

A rat BCa cell line, MRMT-1, and a rat PCA cell line, AT6.1, were procured from RIKEN BioResource Center (Tsukuba, Japan; obtained in January 2014) and European Collection of Authenticated Cell Cultures (Salisbury, UK; obtained in October 2014), respectively, and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (American Type Culture Collection, Rockville, MD, USA), 100 μg/mL streptomycin, and 100 U/mL penicillin.

**Animal models**

Male Sprague-Dawley rats (9–12 weeks old; CLEA Japan, Tokyo, Japan) were used for all experiments. All animals were anesthetized with 1% isoflurane (catalog number: 871119; Pfizer Japan, Tokyo, Japan). In the surgical operations, 0.5% meloxicam (catalog number: DY120028; Boehringer Ingelheim Vetmedica, Tokyo, Japan) was injected subcutaneously in the rats to relieve pain. Osteolytic and osteoblastic lesions were induced in the tibia and/or femur of the experimental rats. A summary of the experimental setup is provided in Table 1.

**Table 1. Summary of the experimental setup.**

| Animal models | Tracers                      | Evaluated lesions                  | Figure |
|---------------|------------------------------|-----------------------------------|--------|
| BCa OL model  | 14C-fluciclovine, 3H-FDG,    | OL, pTF, Tumor                    | 3      |
|               | 89mTc-HMDP                   | OL (fibrous stroma in tumor tissue) | 4      |
|               |                              | OL (pTFB adjacent to OL)          | 5      |
|               |                              | OL (early stage of bone metastasis)| 6      |
| PCA OB model  | 14C-fluciclovine, 3H-FDG,    | OB, pTFB, Tumor                   | 7      |
|               | 89mTc-HMDP                   |                                   |        |
|               | 14C-fluciclovine, 3H-Choline,|                                   | 8      |
|               | 89mTc-HMDP                   |                                   |        |
| DH model      | 14C-fluciclovine, 3H-FDG,    | BBF                               | 9      |
|               | 89mTc-HMDP                   |                                   |        |
|               | 14C-fluciclovine, 3H-Choline,|                                   | 10     |
|               | 89mTc-HMDP                   |                                   |        |

BBF: bland bone formation, BCa: breast cancer, DH: drill-hole, OB: osteoblastic, OL: osteolytic, PCA: prostate cancer, pTFB: peri-tumor bone formation

**BCa osteolytic bone metastatic model**

A cell suspension of MRMT-1 was injected into the saphenous artery of the right and/or left hind leg of rats, as described in a previous report [28], with a minor modification. The femoral, descending genicular, popliteal, and saphenous arteries and veins were freed from the surrounding fat tissue and nerves. To mobilize the blood flow to the descending genicular and popliteal arteries, both of which supply the knee joint and muscles of the hind legs, the femoral and saphenous arteries were temporarily occluded by ligating them with a surgical thread at a position between the descending genicular and the superficial epigastric artery’s origin, and distal of the saphenous artery, respectively. One drop of 4% papaverin solution (catalog number: 871243; Nichi-Iko Pharmaceutical, Toyama, Japan) was applied onto the saphenous artery between the surgical threads. One hundred microliters of a cell suspension containing 2.5 × 10^4 MRMT-1 cells in Hank’s Balanced Salt Solution without Ca^2+ and Mg^2+ [HBSS(-)] was injected into the saphenous artery using a syringe with a 29G needle. After perforating the artery, the saphenous arterial wall was sealed with a piece of fat tissue, the surgical threads were removed, and the operation site was closed. Development of osteolytic lesions was monitored by a microfocus X-ray imaging system (μFX-1000; FUJIFILM Corporation, Tokyo, Japan) or a preclinical imaging system (FX3000 CT, TriFoIL Imaging, Chatsworth, CA, USA) and triple-tracer autoradiography was performed 6 days or 12 ± 1 days after the cell injection.

**PCA osteoblastic bone metastatic model**

An ALZET osmotic pump (catalog number: 2ML4; Durect Corporation, Cupertino, CA, USA) was filled with 50 mg/mL of cyclosporin A (catalog number: 873999; Novartis Pharma, Basel, Switzerland), which were subcutaneously implanted in the rats to suppress the immune system 3–5 days before the cell injection. One hundred microliters of a suspension containing 2 × 10^5 AT6.1 cells in HBSS(-) was then intra-arterially injected into rats by using the procedure mentioned in “BCa osteolytic bone metastatic model”. The development of osteoblastic lesions was monitored visually by FX3000 CT, and triple-tracer autoradiography was conducted 20 ± 3 days after the cell injection.

**Drill-hole (DH) model**

Two holes, each with a diameter of 1 mm, were drilled in the cortical bone of the tibia of the rats to induce the formation of new bone. Each hole was sealed by using a piece of fat tissue. New bone formation was confirmed visually by FX3000 CT, and triple-tracer autoradiography was evaluated 8 ± 1 days postdrilling.

**Triple-tracer autoradiography**

To compare the distribution of each tracer visually in identical lesions, we performed triple-tracer autoradiography using 14C-fluciclovine, 3H-FDG, and 89mTc-HMDP in the BCa osteolytic model (five hind legs), the PCA osteoblastic model (six hind legs), and the drill-hole (DH) model (three hind legs), or 14C-fluciclovine, 3H-choline, and
$^{99m}$Tc-HMDP in the PCa osteoblastic model (six hind legs) and the DH model (three hind legs). Triple-tracer autoradiography was conducted in the osteoblastic model only because bone metastasis in PCa patients is predominantly osteoblastic, as described above and the major PET tracer for PCa is currently $^{11}$C/$^{18}$F-choline as mentioned in the Discussion. Rats were fasted overnight. The tracers $^{14}$C-flucilovine (2.75 MBq/kg), $^{3}$H-FDG or $^{3}$H-choline (18.5 MBq/kg each), and $^{99m}$Tc-HMDP (74 MBq/kg) were injected into the tail vein of an identical rat. $^{14}$C-Flucilovine and $^{3}$H-FDG or $^{3}$H-choline were allowed to remain in circulation for 30 minutes, and $^{99m}$Tc-HMDP was allowed to remain for 2 hours before euthanizing the animal. The animals were sacrificed under anesthesia by drawing blood from the abdominal aorta. The tibiae and femora were removed and frozen in isopentane/dry ice for 10 seconds. They were embedded in super-cry embedded medium (SCEM) (catalog number: 8091140; Section-Lab, Hiroshima, Japan) and frozen again in isopentane/dry ice until the SCEM had set. The frozen samples were placed in the chamber of a CM3050S cryostat (Leica Microsystems, Tokyo, Japan) at -20°C for at least 30 minutes and sectioned with the cryostat at -20°C with an adhesive film (Cryofilm Type 2C(9), catalog number: 8091100; Section-Lab) using Kawamoto’s film method [29]. Fifteen serial sections (12 sections of 5-μm slices and 3 sections of 10-μm slices for the histological and autoradiography specimens, respectively) were obtained. Each section was mounted on a glass slide. To obtain images generated by the $^{99m}$Tc-isotope, super resolution screen (SR) imaging plates (IPs) (FUJIFILM Corporation) were exposed for 1 hour to dried 10-μm slices wrapped in a 12-μm thick polyester film (Luminor; catalog number: S100#12; TORAY Industries, Tokyo, Japan), which absorbs low-energy $^{3}$H isotopes (Fig. 1). Under these conditions, $^{14}$C caused no blackening of the SR-IP, even after a 1-hour exposure. This factor thus excluded cross-contamination by $^{14}$C in the $^{99m}$Tc autoradiographs. The next two frozen sections adjacent to the $^{99m}$Tc-autoradiographed section were stored at -20°C for 5 days to allow complete $^{99m}$Tc decay. Following this procedure, tritium screen (TR)-IPs (FUJIFILM Corporation) were exposed to dried sections with and without the 12-μm thick polyester film for 7 days to obtain $^{14}$C images and $^{3}$H + $^{14}$C mixed images, respectively (Fig. 1) [30]. The IPs were developed with a FLA-7000 imaging analyzer (GE Healthcare, Little Chalfont, UK). The $^{3}$H images were finally generated by subtracting the $^{14}$C images from the $^{14}$C + $^{3}$H images by using ImageJ software (ver. 1.48; National Institutes of Health, Bethesda, MD, USA) (Fig. 1). All images were processed by ImageJ software. Images of $^{14}$C, $^{3}$H, and $^{99m}$Tc obtained from a serial section were stacked in a single window by using the “Stack” function of the ImageJ software. For image registration of the three images, each image was positioned precisely by using several internal soft/hard tissue landmarks with characteristic anatomical information (except for lesions) such as growth plate, a portion of cortical bone of tibiae/femora (ex, distal end), patellae, cartilaginous tissue, and the region-of-interest (ROI) analysis was conducted. The ROIs were manually drawn around each lesion (target) while referring to the histological images of hematoxylin-eosin (H&E) and toluidine blue (TB) staining. Furthermore, three square, circular, or polygonal ROIs of random sizes were manually positioned on the normal regions of muscle surrounding tibiae and/or femora (ex. quadriceps femoris muscle, gastrocnemius muscle) and the average ROI count from the three ROIs was calculated as the background radioactivity. Then, the targetmean-to-backgroundmean (T/BG) ratios were calculated and lesion-based analyses were conducted. For the semi-quantitative criterion, a T/BG ratio ≥1.5 was significant (i.e., positive finding). In each model, the lesions corresponding to $^{99m}$Tc-HMDP accumulation were defined as new bone formation according to the following grading system (see the schema in Fig. 2):

1. OL/OL: tumor lesions with bone absorption in osteolytic model (typical osteolytic lesions);
2. pTBF/OL: peri-tumor bone formation (pTBF) region where $^{99m}$Tc-HMDP accumulated in the OL/OL;
3. Tumor/OL: tumor lesions other than the OL/OL and the pTBF/OL (ex. intramuscle tumor);
4. OB/OB: tumor lesions with pTBF in osteoblastic model (typical osteoblastic lesions);
5. pTBF/OB: pTBF region where $^{99m}$Tc-HMDP accumulated in the OB/OB;
6. Tumor/OB: tumor lesions other than the OB/OB and the pTBF/OB (ex. intramuscle tumor);
7. BBF/DH: bland (non-tumor) bone formation region in the DH model.

http://www.thno.org
Histological analysis

The following procedures for each histological stain were performed qualitatively on 5-μm serial sections using general methods: H&E and TB staining for histological changes at the lesion sites; alkaline phosphatase (ALP) for osteoblast and fibroblast activity; and tartrate-resistant acid phosphatase (TRAP) staining for osteoclast-activity. Anti-ASCT2 (J-25) polyclonal antibody (pAb) (catalog number: sc-130963; 1:40; Santa Cruz Biotechnology, Dallas, TX, USA) and anti-LAT1 (H-75) pAb (catalog number: sc-134994; 1:200; Santa Cruz Biotechnology) for the amino acid transporters were used in the immunohistochemical assessments with EnVision+ System HR-labeled polymer anti-rabbit (catalog number: K4003; Dako Japan, Tokyo, Japan) and Liquid DAB+ Substrate Chromogen System (catalog number: K3468; Dako Japan). Immune cell infiltration of the lesions was detected immunohistochemically using combinations of fluorescein isothiocyanate (FITC)-anti-rat CD45RA monoclonal antibody (mAb) (clone: OX-33; catalog number: 554883; 1:100; BD Biosciences, Franklin Lakes, NJ, USA) for B cells, phycoerythrin (PE)-anti-rat CD8a mAb (clone: OX-8; catalog number: 554857; 1:100; BD Biosciences) for T cells, FITC-anti-rat CD68 mAb for monocytes/macrophages and osteoclasts (clone: ED-1; catalog number: MCA341F; 1:100; Bio-Rad Laboratories, Hercules, CA, USA), and PE-anti-rat granulocyte mAb for neutrophils (clone: RP-1; catalog number: 550002, 1:100; BD Biosciences) (Note: Because the osteoblastic bone metastatic rat model used in this study was immunosuppressed by cyclosporin A, which can inhibit the function of lymphocytes, mAbs against T and B cells were not used.) In the immunofluorescent staining, the nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). A BX-3000 HS all-in-one fluorescence microscope (Keyence Corporation, Osaka, Japan) was used for pathological examinations.

Statistics

The data are presented as the mean ± the standard deviation. All statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA). The two groups were compared statistically using Wilcoxon rank sum test for non-normal distribution datasets or the F-test, followed by two-tailed unpaired Student’s t-test or Welch’s t-test for datasets with normal distribution. In all analyses, $P < 0.05$ was significant.
Results

BCa osteolytic bone metastasis model

In the BCa osteolytic bone metastatic model, 52 tumor-relevant lesions (34 OL/OL, 16 pTBF/OL, and 2 Tumor/OL) were produced inside and/or outside the bone marrow cavity (i.e., at the cortical bone surface) of the tibiae and/or femora and intramuscularly 12 ± 1 days postinjection of the MRMT-1 cells.

The distribution of $^{14}$C-fluclocivone, but not $^{99m}$Tc-HMDP, was similar to that of $^3$H-FDG, although the physiological accumulation of $^{14}$C-fluclocivone was moderate in bone marrow (Fig. 3A). The areas where $^{14}$C-fluclocivone and $^3$H-FDG accumulated were tumors histologically, although $^{99m}$Tc-HMDP did not accumulate in the tumor itself (Fig. 3A). For example, the right tumor in the yellow frames in Fig. 3A showed high accumulation of both tracers; this was a typical osteolytic lesion characterized by resorption pits adjacent to the tumor mass and by TRAP$^+$- and CD68$^+$-cells on the cortical bone surface of the resorption pit, which indicated osteoclast infiltration (Fig. 3B and 3C). Most tumor cells expressed LAT1, whereas there were some ASCT2$^+$-cells in the tumor tissues (Fig. 3C). The CD8$^+$, CD45RA$^+$, or RP-1$^+$-inflammatory cells were few in the right tumor mass. Interestingly, the osteolytic tumor tissues were surrounded by ALP$^+$-cells, which indicated osteoblast and/or fibroblast infiltration (Fig. 3B). Compared with the right tumor, the left tumor tissue in the yellow frames had low $^{14}$C-fluclocivone accumulation, although $^3$H-FDG accumulation was high (Fig. 3A). The histological characteristics of this tumor were that TRAP and ALP activity occurred in the intra-tumor region rather than the peripheral area of this tumor tissue (Fig. 3B) and more inflammatory cells with bean-shaped nuclear cells, CD8$^+$ lymphocytes, and CD68$^+$-cells in the tumor parenchyma (Fig. 3C).

Figure 3. Triple-tracer autoradiography (i.e., $^{14}$C-fluclocivone, $^3$H-FDG, $^{99m}$Tc-HMDP) and histological analyses in BCa osteolytic bone metastatic model rats. (A) Macroscopic images (schema, TB) and representative autoradiograms of $^{14}$C-fluclocivone, $^3$H-FDG, and $^{99m}$Tc-HMDP. The high-power microscopic fields correspond to the green frame on the TB image in Fig. 3A. The color bars represent $^{14}$C-fluclocivone range for each tracer. (B) The low-power microscopic fields (TB, TRAP, ALP) correspond to the yellow frames on the images in Fig. 3A. The TB image shows two tumor masses in the bone marrow cavity. TRAP and ALP staining show osteolytic and osteoblastic activities, respectively. The white scale bars indicate 500 μm. (C) The high-power microscopic fields (H&E, ASCT2, LAT1, CD45RA/CD8α, CD68/RP-1) correspond to the red and cyan frames on the low-power fields in Fig. 3B. The lesion in the red frame contains more immune cell infiltrates, especially CD8α$^+$ T cells and macrophages with bean-shaped nucleus (see H&E images) in addition to tumor cells, while the lesion in the cyan frame is composed mainly of tumor cells (H&E). Many CD68$^+$ cells on the surface of cortical bone (e.g. osteoclasts) are observed (cyan frame). The red and yellow scale bars on each panel indicate 20 μm and 100 μm, respectively. (D) The T/BG ratios of $^{14}$C-fluclocivone and $^3$H-FDG on a per-lesion basis in OL/OL, pTBF/OL, and Tumor/OL lesions. The scatter plots (left) and the mean ± standard deviation (right) are shown. The numbers under each column indicate the number of lesions. ** $P < 0.01$, n.s. not significant.

http://www.thno.org
Table 2. Comparison of the detection rates of $^{14}$C-fluciclovine versus $^{3}$H-FDG, and $^{14}$C-fluciclovine versus $^{3}$H-choline in osteolytic and osteoblastic lesions (lesion-based analysis).

| Lesion Type | $^{14}$C-Fluciclovine | $^{3}$H-FDG | $^{3}$H-Choline |
|-------------|-----------------------|----------------|----------------|
| OL/OL       |                       |                |                |
| Posi        | 34                    | 17             | 10             |
| Nega        | 0                     | 0              | 2              |
| Total       | 34                    | 17             | 12             |
| %Posi of FDG| 100                   | 100            | 50.0           |
| %Posi of $^{14}$C-fluciclovine | 100          | 100            | 91.7           |

| pTBF/OL     |                       |                |                |
|-------------|-----------------------|----------------|----------------|
| Posi        | 16                    | 17             | 11             |
| Nega        | 0                     | 4              | 16             |
| Total       | 16                    | 21             | 27             |
| %Posi of FDG| 100                   | 78.3           | 41.4           |
| %Posi of $^{14}$C-fluciclovine | 100          | 91.3           | 93.1           |

| Tumor/OL    |                       |                |                |
|-------------|-----------------------|----------------|----------------|
| Posi        | 2                     | 49             | 30             |
| Nega        | 0                     | 1              | 17             |
| Total       | 2                     | 49             | 47             |
| %Posi of FDG| 100                   | 98.1           | 66.0           |
| %Posi of $^{14}$C-fluciclovine | 100          | 94.2           | 94.0           |

*Positive (Posi): T/BG ratio ≥ 1.5. Negative (Nega): T/BG ratio < 1.5. Because the accumulation of tracers in each lesion was confirmed histologically, the positive and negative results indicate true-positive and false-negative, respectively, in this study.

On the lesion-based analysis of the osteolytic bone metastatic model, the distribution of T/BG ratios of $^{14}$C-fluciclovine in OL/OL, pTBF/OL, and Tumor/OL lesions were narrow, while those of $^{3}$H-FDG were broad as shown in the counter plot (Fig. 3D). A statistical significant difference was detected only between OL/OL lesions of both tracers (Fig. 3D). The detection rates of the lesions with a T/BG ≥1.5 were 100% for OL/OL, pTBF/OL, and Tumor/OL lesions for both tracers (Table 2). (Note: positive and negative findings for the tracers indicated true-positive and false-negative, respectively, because each lesion was confirmed histologically.)

By using the osteolytic bone metastatic model, we observed some characteristic accumulation of tracers at lesions that closely mimics clinical findings. One of the lesions was observed in an OL/OL lesion invading the outer region of the bone marrow cavity (the green frame in the Fig. 3A): fibrous stroma in tumor tissue. It showed that equal or greater accumulation of $^{14}$C-fluciclovine, but not $^{3}$H-FDG and $^{99m}$Tc-HMDP, in fibrous stromal tissues surrounding the tumors (the yellow region on the schema in Fig. 4), compared to that of the tumor parenchyma containing necrotic cells (the red region on the schema in Fig. 4). ALP and TRAP activities existed in the fibrous area (Fig. 4). Some cells in both areas were positive for ASCT2 and LAT1, and there were CD8α+ T-lymphocytes in the tumor parenchyma, but not in the stroma (Fig. 4). CD68+/positive cells, but not multinuclear cells, indicated the presence of monocytes/macrophages in the border of the fibrous tissue and tumor parenchyma (Fig. 4).

Another characteristic accumulation of tracers in the osteolytic bone metastatic model occurred in a pTBF/OL lesion, as shown in Fig. 5. It was characterized by a bone formation lesion adjacent to an OL/OL lesion with a resorption pit (cyan and red frames on the schema). The pTBF/OL lesion was small but had hyper new bone formation composed of osteoids and extensive ALP and TRAP activities. $^{14}$C-Fluciclovine accumulated in the OL/OL and the pTBF/OL lesions, whereas $^{3}$H-FDG and $^{99m}$Tc-HMDP accumulated in only the OL/OL and the pTBF/OL lesions, respectively. In the OL/OL lesion, LAT1+, but not ASCT2+, positive cells were scattered broadly in
the tumor area. In the pTBF/OL lesion, ASCT2⁺-cells were located in the outer border of the pTBF, and LAT1-expressing cells were inside and outside the pTBF. In the OL/OL and pTBF/OL lesions, there were few CD8α⁺ or CD45RA⁺-lymphocytes and granulocytes; however, there were many CD68⁺ cells (probably osteoclasts).

**Early detection of osteolytic bone metastatic model lesions with ¹⁴C-fluciclovine**

The previously described osteolytic bone metastatic models were used 12 ± 1 days postinjection of MRMT-1 cells; thus, the lesions showed drastic bone absorption with a large number of cancer cells. However, ¹⁴C-fluciclovine and ³⁵H-FDG, but not ⁹⁹mTc-HMDP, could reveal a lesion without extensive bone absorption in the tibia as early as 6 days post-injection of MRMT-1 (Fig. 6). The T/BG ratios of ¹⁴C-fluciclovine and ³⁵H-FDG were 5.8 and 6.1, respectively. Histological examinations showed that the lesion between the trabeculae was invaded by tumor cells positive for ASCT2 and LAT1, and TRAP and CD68 staining revealed extensive osteoclast infiltration on the trabeculae, which suggested that bone absorption was in progress on the surface of the trabeculae and that the lesion was in an early phase of tumor metastasis. The lesion contained few inflammatory cells, except for CD68⁺ cells.

**PCa osteoelastic bone metastasis model**

In the PCa osteoelastic bone metastatic model, 92 tumor-relevant lesions (17 OB/OB, 23 pTBF/OB, and 52 Tumor/OB) and 103 tumor-relevant lesions (24 OB/OB, 29 pTBF/OB, and 50 Tumor/OB) formed in the hind legs of rats used for triple tracer autoradiography with ¹⁴C-fluciclovine/³⁵H-FDG/⁹⁹mTc-HMDP and with ¹⁴C-fluciclovine/³⁵H-choline/⁹⁹mTc-HMDP, respectively, 20 ± 3 days postinjection of the AT6.1 cells. Most OB/OB lesions were on the cortical bone surface of the outer bone marrow cavity of the tibiae and/or femora.

---

**Figure 4.** Triple tracer autoradiography (i.e., ¹⁴C-fluciclovine, ³⁵H-FDG, ⁹⁹mTc-HMDP) and histological analyses in an osteolytic lesion in the outer of bone marrow cavity in a BCa osteolytic bone metastatic model rat. (A) The schema, magnified histological images (ALP, TRAP), and the autoradiograms of ¹⁴C-fluciclovine, ³⁵H-FDG, and ⁹⁹mTc-HMDP correspond to the green frame on the TB image in Fig. 3A. The fibrous area (yellow region), but not the tumor area (red region), shows ALP (probably fibroblasts) and TRAP (probably monocytes/macrophages) staining. Color scale bars on each autoradiogram represent Bq range for each tracer. (B) The high-power microscopic fields (H&E, ASCT2, LAT1, CD45RA/CD8α, CD68/RP-1) correspond to the red and cyan frames on the images in Fig. 4A are shown. CD68⁺ monocytes/macrophages and CD8α⁺ T cells are infiltrating into the fibrous area (red frame) and the tumor area (cyan frame). The red and yellow scale bars on each panel indicate 20 μm and 100 μm, respectively.

http://www.thno.org
In the triple-tracer autoradiography with $^{14}$C-fluciclovine/$^3$H-FDG/$^{99m}$Tc-HMDP, the distribution of $^{14}$C-fluciclovine, but not $^{99m}$Tc-HMDP, was similar to that of $^3$H-FDG (Fig. 7A). Histological analyses demonstrated that the OB/OB lesions visually confirmed with $^{14}$C-fluciclovine and $^3$H-FDG accumulation (the areas corresponding to the red frames on the images in Fig. 7B), but not with $^{99m}$Tc-HMDP, were primarily composed of tumor cells with positivity for LAT1, but negative to weak expression for ALP, TRAP, and ASCT2 (Fig. 7B and 7C, refer also to Fig. 8). This area also contained some CD68$^{+}$-cells (i.e., monocytes/macrophages) (Fig. 7C).

On the contrary, the pTBF/OL lesions with low concentrations of $^{14}$C-fluciclovine, low accumulation of $^3$H-FDG, and a high concentration of $^{99m}$Tc-HMDP contained extensive calcification and fewer cellular components (the areas corresponding to the cyan frames on the images in Fig. 7B), although the cells in the lesion were positive for ALP and TRAP. Some cells in this area expressed ASCT2 and LAT1 (Fig. 7C). CD68$^{+}$ cells were detected on the surface of the new bone as well as TRAP activity (Fig. 7C). Thus, the cellular components in the pTBF/OL lesion were probably a mixture of cancer cells, osteoblasts, and osteoclasts.
Figure 6. Triple-tracer autoradiography (i.e., $^{14}$C-fluclovin, $^{1}$H-FDG, $^{99m}$Tc-HMDP) and histological images in the early stage of bone metastasis in a BCa osteolytic bone metastatic model rat. (A) The schema, the TB image, and the autoradiograms of $^{14}$C-fluclovin, $^{1}$H-FDG, and $^{99m}$Tc-HMDP are shown. Color scale bars on each autoradiogram represent Bq range for each tracer. (B) The high-power microscopic images (H&E, TRAP, ASCT2, LAT1, CD45RA/CD8α, CD68/RP-1) correspond to the yellow frames on the images in Fig. 6A are shown. The existence of TRAP$^+$ and CD68$^+$ cells on trabeculae indicates osteolytic response. The red and yellow scale bars on each panel indicate 20 μm and 100 μm, respectively.

Figure 7. Triple-tracer autoradiography (i.e., $^{14}$C-fluclovin, $^{1}$H-FDG, $^{99m}$Tc-HMDP) and histological analyses in PCA osteoblastic bone metastatic model rats. (A) Macroscopic images (schema, TB) and representative autoradiograms of $^{14}$C-fluclovin, $^{1}$H-FDG, and $^{99m}$Tc-HMDP. Color scale bars on each autoradiogram represent Bq range for each tracer. (B) The low-power microscopic fields (TB, ALP, TRAP) correspond to the yellow frames on the images in Fig. 7A. Extensive osteoblastic activity is observed in TB and ALP images. The white scale bars indicate 500 μm. (C) The high-power microscopic fields (H&E, ASCT2, LAT1, CD68/RP-1) correspond to the red and cyan frames on the low-power fields in Fig. 7B. Palisade-like structures, a characteristic feature of osteoblastic lesions, are observed (H&E in the cyan frame). The red and yellow scale bars on each image indicate 20 μm and 100 μm, respectively. (D) The T/BG ratios of $^{14}$C-fluclovin and $^{1}$H-FDG on a per-lesion basis in OB/OB, pTBF/OB, and Tumor/OB lesions. The counter plots (left) and the mean ± standard deviation (right) are shown. The numbers under each column indicate the number of lesions. *P < 0.05, **P < 0.01, n.s. not significant.
The distribution of both T/BG ratios of $^{14}$C-fluciclovine and $^3$H-FDG in OB/OB and pTBF/OB lesions on the counter plot were compact, although that of $^3$H-FDG in Tumor/OB lesions was broader than that of $^{14}$C-fluciclovine (Fig. 7D). There were statistical significant differences between each lesion for $^3$H-FDG, but not for $^{14}$C-fluciclovine, and between OB/OB lesions of both tracers (Fig. 7D). The detection rates (percentage) of OB/OB, pTBF/OB, and Tumor/OB lesions with T/BG ≥1.5 were 17/17 (100%), 21/23 (91.3%), and 49/52 (94.2%), respectively, with $^{14}$C-fluciclovine; and 17/17 (100%), 18/23 (78.3%), and 51/52 (98.1%), respectively, with $^3$H-FDG (Table 2). This finding indicated that $^{14}$C-fluciclovine had more true-positive findings than $^3$H-FDG at the pTBF/OB lesions. The 2 × 2 contingency table between $^{14}$C-fluciclovine and $^3$H-FDG showed one pTBF/OB lesion (1/23, 4.3%) and two tumor/OB lesions (2/52, 3.8%) with $^{14}$C-fluciclovine-negative/$^3$H-FDG-positive, and four pTBF/OB lesions (4/23, 17.4%) with $^{14}$C-fluciclovine-positive/$^3$H-FDG-negative (Table 2). Histological analysis showed that the cellular component in the lesions with $^{14}$C-fluciclovine-negative/$^3$H-FDG-positive were primarily tumor cells, although some CD68+ cells were infiltrated. Furthermore, the lesions with $^{14}$C-fluciclovine-positive/$^3$H-FDG-negative were typical new bone lesions with pTBF and tumor cells.

In the analyses using triple-tracer autoradiography with $^{14}$C-fluciclovine, $^3$H-choline, and $^{99m}$Tc-HMIDP, the distribution patterns of $^{14}$C-fluciclovine and $^3$H-choline, but not $^{99m}$Tc-HMIDP, were similar to each other in the OB/OB, the pTBF/OB, and Tumor/OB lesions (Fig. 8A), although the T/BG ratios of $^3$H-choline in the lesions were less than those of $^{14}$C-fluciclovine (Fig. 8D). The histological characteristics of the osteoblastic model used in this study were similar to those used for the autoradiography with $^{14}$C-fluciclovine/$^3$H-FDG/$^{99m}$Tc-HMIDP, although the pTBF/OB lesion shown in Fig. 8 appears to be more of an immature lesion than that in Fig. 7.

The detection rates (percentage) of lesions in the OB/OB, the pTBF/OB, and the Tumor/OB with T/BG ≥1.5 were 22/24 (91.7%), 27/29 (93.1%), and
and Drill-hole model

We used a DH model to investigate the accumulation of $^{14}$C-fluciclovine and $^3$H-FDG in the BBF without tumor cells. The accumulation of $^{99m}$Tc-HMDP in the BBF/DH lesion was intense, whereas the accumulation $^{14}$C-fluciclovine and $^3$H-FDG was vague and not discriminated from the surrounding bone marrow (Fig. 9A). The distribution of both T/BG ratios of $^{14}$C-fluciclovine and $^3$H-FDG in BBF/DH lesions is shown in Fig. 9D. The accumulation of $^{14}$C-fluciclovine in the BBF was higher than that of $^3$H-FDG (Fig. 9D). The T/BG ratios of $^{14}$C-fluciclovine (3.6 ± 0.2) and $^3$H-FDG (2.3 ± 0.5) in the BBF/DH lesions were higher than (P < 0.01) and equal to (P > 0.05), respectively, those in the pTBF/OB lesions. The BBF/DH lesions contained ALP and TRAP activity (the red frames in Fig. 9B), and some LAT1$^+$ and CD68$^+$ cells, but not ASCT2$^+$ cells, were on the surface of the new bones (Fig. 9C). These findings suggested that not only tumor cells but also other cells presenting in new bone regions (e.g. osteoblasts) contributed to the accumulation of $^{14}$C-fluciclovine in the pTBF/OB lesions. A relatively high accumulation of $^3$H-FDG, but not $^{14}$C-fluciclovine, was observed on the bone surface in the drill hole (the red arrows in a yellow frame on the autoradiograms of $^3$H-FDG in Fig. 9A). This finding may be caused by the infiltration of monocytes/macrophages because the cells in this area were CD68$^+$, but TRAP$^-$ (Fig. 9B and 9C).

Figure 9. Triple-tracer autoradiography (i.e., $^{14}$C-fluciclovine, $^3$H-FDG, $^{99m}$Tc-HMDP) and histological analyses in DH model rats. (A) Macroscopic images (schema, TB) and representative autoradiograms of $^{14}$C-fluciclovine, $^3$H-FDG, and $^{99m}$Tc-HMDP. The red arrows in a yellow frame on the autoradiograms of $^3$H-FDG shows the region of high $^3$H-FDG accumulation in the drill-hole. Color scale bars on each autoradiogram represent $8x$ range for each tracer. (B) The low-power microscopic fields (TB, ALP, TRAP) correspond to the yellow frames on the images in Fig. 9A. Intense osteoblastic (ALP) and osteolytic (TRAP) activities are observed around the DH, showing the formation of new bones. The white scale bars indicate 500 μm. (C) The high-power microscopic fields (H&E, ASCITL LAT1, CD45RA/CD8α, CD68/FR-1) correspond to the red and cyan frames on the low-power fields in Fig. 9B. The cells in the region showing high $^3$H-FDG accumulation (the red arrows in Fig. 9A) are mononuclear cells (H&E) and are positive for CD68, revealing the infiltration of monocytes/macrophages. The red and yellow scale bars on each image indicate 20 μm and 100 μm, respectively. (D) The T/BG ratios of $^{14}$C-fluciclovine and $^3$H-FDG on a per-lesion basis in BBF/DH lesions. The numbers under each column indicate the number of lesions. **P < 0.01.
For the triple-tracer autoradiography with \(^{14}\text{C}\)-fluorocitrate/\(^{3}\text{H}\)-choline/\(^{99m}\text{Tc}\)-HMDP, the distribution patterns of tracers and the histological characteristics in the DH model used in this study were similar to those used for the autoradiography with \(^{14}\text{C}\)-fluorocitrate/\(^{18}\text{F}\)-FDG/\(^{99m}\text{Tc}\)-HMDP (Fig. 10). The T/BG ratios of \(^{14}\text{C}\)-fluorocitrate (4.1 ± 0.5) and \(^{3}\text{H}\)-choline (2.5 ± 0.6) in the BBF/DH lesions were higher than those in the pTBF/OB lesions (\(P < 0.01\)).

Discussion

By using osteolytic and osteoblastic bone metastasis models, we histologically compared the accumulation of \(^{14}\text{C}\)-fluorocitrate in the osteolytic and osteoblastic lesions with that of \(^{3}\text{H}\)-FDG and \(^{3}\text{H}\)-choline. The distribution patterns of these tracers were similar and their accumulations histologically corresponded to these lesions. In the osteolytic bone metastatic model, \(^{14}\text{C}\)-fluorocitrate visualized the OL/OL lesions in bone marrow cavity as well as \(^{18}\text{F}\)-FDG/\(^{3}\text{H}\)-choline [17,18]. A typical osteolytic lesion observed in clinical specimens includes tumor cells and osteoclasts. It is reported that osteoclasts express LAT1 [31] and ASCT2 [32], which are transporters of fluorocitrate [14, 16]. Thus, diagnosing osteolytic bone metastatic lesions with \(^{18}\text{F}\)-fluorocitrate is reasonable mechanistically. In addition, \(^{14}\text{C}\)-fluorocitrate could reveal a small osteolytic lesion in the space between trabecula at the early phase of bone metastasis. It is thought that bone absorption precedes new bone formation, even in PCa osteoblastic lesions [33]. As described above, because the 5-year survivals between cancer patients with and without bone metastases are quite different [2], early detection of bone metastasis may improve therapy outcomes and potentially increase survival. Our result indicated that \(^{18}\text{F}\)-fluorocitrate-PET, as well as \(^{18}\text{F}\)-FDG-PET, may useful for the early diagnosis of osteolytic metastasis [4, 34, 35].

In the osteoblastic bone metastatic model, \(^{14}\text{C}\)-fluorocitrate could visualize the OB/OB lesion clearer compared with \(^{3}\text{H}\)-FDG and \(^{3}\text{H}\)-choline. This result was supported by a small osteoblastic lesion adjacent to an osteolytic lesion observed in an osteolytic metastatic model (see the red frame in Fig. 5), which occurs in patients with bone metastasis [3]. Usually, a typical immature osteoblastic lesion

http://www.thno.org
includes osteoids, osteoblasts, and osteoclasts, in addition to tumor cells. Osteoblasts and osteoclasts express LAT1 [31], whereas osteoclasts express ASCT2 [32]. Thus, the accumulation of \(^{14}\text{C}\)-fluclucilovine at the osteoblastic lesion may have primarily been caused by LAT1- and/or ASCT2-expressing cells such as cancer cells, osteoclasts, and osteoblasts. In addition to ASCT2 and LAT1, also some amino acid transporters (AATs) such as ASCT1 and LAT3 may be associated with \(^{14}\text{C}\)-fluclucilovine uptake in AT6.1 cells in osteoblastic lesions because the AT6.1 cells also expressed these AATs at the gene level (Supplementary Fig. S1) and the substrates for these AATs are similar to those for ASCT2 and LAT1 [14]. Interestingly, \(^{14}\text{C}\)-fluclucilovine vaguely visualized the OB/OB lesions, compared to the small osteoblastic lesion observed in the osteolytic metastatic model. For this reason, it may be that the latter finding indicated an immature osteoblastic lesion with abundant cell components 12 ± 1 days postinjection of the cancer cells, whereas the former finding probably indicated matured osteoblastic lesions with fewer cell components and extensive calcification 20 ± 3 days postinjection (Fig. 7B, the white stained area on the TB image indicates calcification). Regarding the abundant cellular components, the BBF lesions of the DH model 8 ± 1 days after drilling showed relative high T/BG ratios of \(^{14}\text{C}\)-fluclucilovine. These findings suggested that \(^{14}\text{C}\)-fluclucilovine accumulates in osteoblastic lesions but at an earlier stage of the development of osteoblastic lesions, compared to the sclerotic lesion at the late stage.

The most widely used PET tracer for diagnosing PCa is \(^{11}\text{C}\)-choline [6]. \(^{11}\text{C}\)-Choline-PET has been used for detecting osteolytic and osteoblastic metastatic lesions in patients with PCa [6]; however, Nanni et al. [36] recently reported that the T/BG ratios of \(^{18}\text{F}\)-fluclucilovine were greater than \(^{11}\text{C}\)-choline in PCa relapse including bone metastasis. We also showed that \(^{14}\text{C}\)-fluclucilovine was superior to \(^{3}\text{H}\)-choline for detecting lesions in osteoblastic metastasis model. In addition, Bundschuh et al. reported \(^{11}\text{C}\)-choline uptake corresponding to the histological localization of PCa was present in less than 50% of primary lesions [37], revealing low true-positive rating with \(^{11}\text{C}\)-choline as seen in the current experiment. Therefore, it seems that better image quality and contrast and the percentage of patients with true-positive findings were generally higher with \(^{18}\text{F}\)-fluclucilovine than with \(^{11}\text{C}\)-choline, at least in PCa patients with osteoblastic lesions. In contrast, Beheshti et al. reported the negative correlation between \(^{18}\text{F}\)-fluorocho line uptake and the density of sclerotic lesions in prostate cancer patients [38]. Generally, the denser the lesion, the fewer are the tumor cells. Therefore, \(^{18}\text{F}\)-fluclucilovine uptake may also correlate negatively with the density of sclerotic areas in osteoblastic lesions.

Our bony metastatic model showed some differential distributions of \(^{14}\text{C}\)-fluclucilovine and \(^{3}\text{H}\)-FDG at the pathognomonic areas. One of the discrepant accumulation patterns of both tracers occurred in a lesion with infiltration of inflammatory cells in the osteolytic model. This lesion contained many inflammatory cells and showed low \(^{14}\text{C}\)-fluclucilovine and high \(^{3}\text{H}\)-FDG accumulation. Several types of inflammatory cells such as lymphocytes, neutrophils, macrophages, dendritic cells, and mast cells exist in the tumor microenvironment [39]; however, T-lymphocytes and/or monocytes/macrophages were the main inflammatory cells infiltrating or surrounding tumor lesions in our bone metastatic models. The relatively high accumulation of \(^{3}\text{H}\)-FDG in the tumors with inflammation is reasonable because many non-clinical and clinical reports exist on the extensive accumulation of \(^{18}\text{F}\)-FDG in inflammation, which is one cause of false-positives in FDG-PET imaging [15,40,41]. Thus, a broader distribution of T/BG ratios of \(^{3}\text{H}\)-FDG compared to \(^{14}\text{C}\)-fluclucilovine may indicate inflammation (Fig. 3D). However, \(^{18}\text{F}\)-fluclucilovine is also taken up by activated lymphocytes, although the amount is smaller than that of \(^{18}\text{F}\)-FDG [15,41]. This finding may be because of the upregulation of LAT1 and ASCT2, which are the main AATs for fluclucilovine uptake in cancer cells [14,16], along with the activation of T-lymphocytes [42,43]. This factor may cause false-positive findings in fluclucilovine-PET imaging of cancer patients. In fact, few false-positives in fluclucilovine-PET due to inflammation have been reported in a clinical study [36]. However, \(^{18}\text{F}\)-fluclucilovine may have fewer false-positives, compared to FDG-PET, because of its lower uptake by inflammatory cells [15,41]. Furthermore, \(^{18}\text{F}\)-fluclucilovine may be preferable to \(^{18}\text{F}\)-FDG for the evaluation of the therapeutic efficacy of chemotherapy/radiotherapy in cancer patients, because these treatments can induce an inflammatory response in cancer tissue [44], and the uptake of \(^{18}\text{F}\)-FDG, by inflammatory cells, especially acute inflammatory cells such as granulocytes and macrophages, is higher than that of \(^{18}\text{F}\)-fluclucilovine [15,41]. Thus, FDG-PET may be more sensitive but less specific than fluclucilovine-PET for detecting bone metastasis.

Another discrepant accumulation between \(^{14}\text{C}\)-fluclucilovine and \(^{3}\text{H}\)-FDG occurred in fibrous tissue surrounding the tumor parenchyma, which invaded outside of bone marrow cavities in the BCa osteolytic metastatic model. \(^{14}\text{C}\)-Fluclucilovine
accumulated more in fibrous tissue with high ALP activity, whereas $^3$H-FDG accumulated more in tumor parenchyma containing necrotic tumor cells. It may be that the ALP$^+$-cells were not derived from MRMT-1, because the BCA cells did not express ALP gene, despite expressing some osteoblastic-related genes (Supplementary Fig. S2). Fibroblasts and myofibroblasts, called “cancer-associated fibroblasts,” often represent the major cellular components of the tumor stroma of primary and metastatic lesions of tumors [45]. ALP is expressed in the tumor stroma [46], LAT1 in fibroblasts [47], and ASCT2 in fibrosis [48]. Therefore, these AATs probably contributed to the accumulation of $^{14}$C-flucilovine in the tumor stroma as well as tumor cells. If our speculation would be correct, the accumulation of $^{18}$F-flucilovine in the tumor stroma may be a factor to increase the sensitivity of detecting cancers, especially in stroma-rich cancers such as scirrhous cancer. However, we need further investigation to demonstrate our speculation concerning the mechanisms of $^{18}$F-flucilovine accumulation in fibrous tissue.

In the DH model, the accumulation of $^{14}$C-flucilovine in the BBF was higher than that of $^3$H-FDG and $^3$H-choline (Fig. 9 and 10). This result suggests that the usefulness of $^{18}$F-flucilovine may be limited, as some pathological conditions (e.g., fracture, bone infection, and arthropathy) involve osteoblastic reactions. Similar limitations have been noted for bone scan with $^{99m}$Tc-MDP [4]. The BBF contained osteoblasts expressing LAT1, which explained the accumulation of $^{14}$C-flucilovine in the BBF. Furthermore, the slow washout of $^{14}$C-flucilovine from the BBF and normal bone marrow probably contributed to the relatively high accumulation of $^{14}$C-flucilovine [49]. However, we have previously reported mild focal uptake of $^{18}$F-flucilovine (milder than that of $^{18}$F-FDG) in degenerative facet disease [49]. Further clinical study is needed to investigate the possibility of false-positive results with $^{18}$F-flucilovine in osteoblastic lesions.

In the current study, we used $^{14}$C-flucilovine, $^3$H-FDG, and $^3$H-choline instead of $^{18}$F-flucilovine, $^{18}$F-FDG, and $^{11}$C/$^{18}$F-choline, respectively, to compare the accumulation of these tracers at the same osteolytic/osteoblastic bone metastatic lesions by using triple-tracer autoradiography technique. We believe that our findings in a rat model reflect the biomolecular changes in bone metastatic lesions of patients with PCa and BCa. However, to extrapolate our findings to clinical practice, we should keep in mind the qualitative and quantitative differences between $^3$H/$^{14}$C- and $^{11}$C/$^{18}$F-images, as well as the differences in body size (e.g., long bones, bone marrow cavity) between rats and humans.

In conclusion, $^{14}$C-flucilovine accumulated in osteolytic lesions and osteoblastic, especially early-stage, osteoblastic bone metastatic lesions with abundant cellular components. These findings were confirmed histologically. The T/BG ratios of $^{14}$C-flucilovine in the osteolytic model were lower than those of $^3$H-FDG. However, $^{14}$C-flucilovine could more clearly reveal osteoblastic lesions. $^{14}$C-Flucilovine was superior in $^3$H-choline in the osteoblastic model. Thus, $^{18}$F-flucilovine-PET can be useful for the visualization of bone metastases in many types of cancer such as BCa and PCa. Because $^{99m}$Tc-HMDP can be predominantly used for detecting advanced osteoblastic lesions (especially sclerotic bone lesions), the combined use of $^{18}$F-flucilovine-PET and bone scan with $^{99m}$Tc-HMDP would be helpful for a more accurate diagnosis of bone metastases.

**Abbreviations**

AAT: amino acid transporter; ALP: alkaline phosphatase; ASCT1: alanine-serine-cysteine transporter 1; ASCT2: alanine-serine-cysteine transporter 2; BBF: bland bone formation; BCa: breast cancer; $^{11}$C: carbon-11; $^{14}$C: carbon-14; CT: computed tomography; DAB: 3,3’-diaminobenzidine; DAPI: 4’,6-diamidino-2-phenylindole; DH: drill-hole; $^{18}$F: fluorine-18; FDG: 2-deoxy-2-fluoro-D-glucose; FITC: fluorescein isothiocyanate; $^{68}$Ga: gallium-68; $^3$H: tritium-3; H&E: hematoxylin-eosin; HBSS: Hank’s balanced salt solution; HMDP: hydroxymethylene diphosphonate; IP: imaging plate; LAT1: L-type amino acid transporter 1; LAT3: L-type amino acid transporter 3; $^{177}$Lu: Lutetium-177; MDP: methylene diphosphonate; mAb: monoclonal antibody; $^{99m}$Tc: technetium-99m; Nega: negative; OB: osteoblastic; OL: osteolytic; pAb: polyclonal antibody; PE: phycerythrin; PET: positron emission tomography; Posi: positive; PCa: prostate cancer; PSMA: prostate-specific membrane antigen; pTBF: peri-tumor bone formation; RCP: radiochemical purity; RPMI1640: Roswell Park Memorial Institute 1640; ROI: region-of-interest; SCEM: super-cryo embedding medium; SR: super resolution screen; TB: toluidine blue; T/BG: target to background; TR: tritium screen; TRAP: tartrate-resistant acid phosphatase

**Supplementary Material**

Supplementary figures and tables.

http://www.thno.org/v07p2048s1.pdf
Acknowledgements

We thank Masahiro Ono for his assistance in the histological examinations and computed tomography imaging; Sachiko Naito for her assistance in the daily maintenance of the cell cultures and reverse-transcription polymerase chain reaction; Shiro Yoshida for his assistance in the daily maintenance of the animals; and our colleagues for their comments on the manuscript. We thank Editage for English editing.

Ethics

All animal handling and experimentation procedures were conducted in accordance with the Japanese Laws for Act on Welfare and Management of Animals and approved by the Committee on Animal Welfare at Nihon Medi-Physics.

Author Contributions

Conception and design: Shuntaro Oka, Masaru Kanagawa
Development of methodology: Shuntaro Oka, Masaru Kanagawa
Acquisition of data: Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi
Analysis and interpretation of data (e.g., histological analysis, statistical analysis): Shuntaro Oka

Writing, review, and/or revision of the manuscript: Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M. Goodman, Hirokatsu Yoshimura

Administrative, technical, or material support: David M. Schuster, Mark M. Goodman, Hirokatsu Yoshimura

Study supervision: Hirokatsu Yoshimura

Conflict of interest

Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, and Hirokatsu Yoshimura are employees of Nihon Medi-Physics (Tokyo, Japan). We are collaborating with Mark M. Goodman and David M. Schuster for nonclinical and clinical studies on 18F-fluorocitrate. Mark M. Goodman and Emory University are eligible to receive royalties from Nihon Medi-Physics. David M. Schuster is receiving research support through Emory University from Nihon Medi-Physics and Blue Earth Diagnostics (Oxford, United Kingdom). There is no other potential conflict of interest relevant to this article to declare.

References

1. Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012; 4: 87−93.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5−29.
3. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006; 12: 6213−6.
4. Peterson JJ, Kransdorf MJ, O’Connor MJ. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res. 2003; 415 (Suppl): S120–S128.
5. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005; 32: 1253−8.
6. Mapelli P, Incerti E, Ceci F, et al. [18F] Fluorocholine PET/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med. 2016; 57: 463−885.
7. Schwarz T, Seidl C, Schieman M, et al. Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies. Nucl Med Biol. 2016; 43: 355–9.
8. Azad GK, Cook GJ. Multi-technique imaging of bone metastases: spotlight on PET-CT. Clin Radiol. 2016; 71: 620−31.
9. Schuster DM, Nanni C, Fanti S. PET Tracers Beyond FDG in Prostate Cancer. Somat Nucl Med. 2016; 46: 507−521.
10. Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012; 23: 834−43.
11. Hildebrandt MG, Gerke O, Baun C, et al. [18F]Fluorodeoxyglucose (FDG)-positional emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy. J Clin Oncol. 2016; 34: 1869−97.
12. Wondergem M, van der Zant EM, van der Ploeg T, et al. A literature review of [18F]-fluoride PET/CT and [18F]-Choline or [18C]-Choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34: 935−45.
13. Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43: 1503−13.
14. Oka S, Okudaira H, Yoshida Y, et al. Transport mechanisms of trans-1-amino-3-fluorocitrate ([18F]fluorocitrate) in prostate cancer cells. Nucl Med Biol. 2012; 39: 109−19.
15. Oka S, Okudaira H, Ono M, et al. Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocitrate in inflammation, prostate cancer, and glioma cells: comparison with L-methyl-[18F]Cl/dihydroxyphenylalanine and 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol. 2014; 16: 322−9.
16. Okudaira H, Nakarishi T, Oka S, et al. Kinetic analyses of trans-1-amino-3-[18F]fluorocitrate transport in Xenopus laevis oocytes expressing human ASAP2 and SNA12. Nucl Med Biol. 2013; 40: 670−5.
17. Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-[18F]fluorocitrate-carboxylic acid PET/CT and 18F-fluorodeoxyglucose PET/CT. J Nucl Med. 2015; 50: 1324−30.
18. Amzat R, Taleghani P, Savir-Baruch B, et al. Unusual presentations of metastatic prostate carcinoma as detected by anti-3-F-18 FACBC PET/CT. Clin Nucl Med. 2013; 38: 800−2.
19. Suzuki H, Inoue Y, Fujimoto H, et al. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocitrate-carboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial. Jpn J Clin Oncol. 2016; 46: 152−62.
20. Tade FJ, Cohen MA, Styblo TM, et al. Anti-3-F-FACBC ([18F]fluorocitrate) PET/CT of breast cancer: an exploratory study. J Nucl Med. 2016; 57: 1357−63.
21. Ulener GA, Goldman DA, Gönen M, et al. Initial results of a prospective clinical trial of [18F]fluorocitrate PET/CT in newly diagnosed invasive ductal and invasive lobular breast cancers. J Nucl Med. 2016; 57: 1350−6.
22. Shoup TM, Olson J, Hoffman JM, et al. Synthesis and evaluation of [18F]-1-amino-3-fluorocitrate-carboxylic acid to image brain tumors. J Nucl Med. 1999; 40: 331−8.
23. Kondo A, Ishii H, Aoki S, et al. Phase IIa clinical study of [18F]fluorocitrate: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med. 2016; 30: 608−18.
24. Jani AB, Fos TH, Whitaker D, et al. Case study of anti-1-amino-3-F-18 fluorocitrate-carboxylic acid (anti-[18F] FACC) to guide prostate cancer radiotherapy target design. Clin Nucl Med. 2009; 34: 279−94.
25. Jani AB, Schreibmann E,Rossi P, et al. Impact of [18F]fluorocitrate PET on target volume definition for postprostatectomy salvage radiotherapy: initial findings from a randomized trial. J Nucl Med 2017; 58: 412−8.
26. Akin-Akinbayeo OO, Jani AB, Odewale O, et al. Change in salvage radiotherapy management based on guidance with FACBC (fluorocitrate) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med. 2017; 42: 222−8.
27. Greco C, Forte L, Erba P, et al. Bone metastases, general and clinical issues. QJ Nucl Med Mol Imaging. 2011; 55: 337−52.
28. [Internet] Zepp M, Buerfeind TJ, Elazar V, et al. Treatment of breast cancer lymphatic skeletal metastasis using a model in nude rats. In: Gunduz E, editor. Breast cancer—current and alternative therapeutic modalities. InTech; 2011. DOI: 10.5772/24269. http://www.intechopen.com/books/breast-cancer-current-and-alternative-therapeutic-modalities/treatment-of-breast-cancer-lytic-skeletal-metastasis-using-a-model-in-nude-rats [accessed on 4:30-2017].
